stockportfolio.pro
Ligand Pharmaceuticals Incorporated (LGND)
Healthcare · Biotechnology · NasdaqGM
Ligand Pharmaceuticals Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $108.97M | $141.10M | $251.45M | $120.28M | $163.56M | $241.54M | $196.25M | $131.31M | $167.13M | $268.09M |
| Gross profit | $103.40M | $135.74M | $245.12M | — | — | — | — | — | — | — |
| Net income | $-1.64M | $12.56M | $143.32M | $629.30M | $-2.98M | $57.14M | $-33.36M | $52.15M | $-4.03M | $124.45M |
| Net margin | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
Source: Ligand Pharmaceuticals Incorporated SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Ligand Pharmaceuticals Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LGND in your portfolio →
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Ligand Pharmaceuticals Incorporated — frequently asked questions
What is Ligand Pharmaceuticals Incorporated's revenue?
Ligand Pharmaceuticals Incorporated (LGND) reported revenue of $268.09M for fiscal year 2025, up 60.4% from the prior year, according to its SEC filings.
Is Ligand Pharmaceuticals Incorporated profitable?
Yes. LGND earned net income of $124.45M in fiscal 2025, a net margin of 46.4%.
What is LGND's P/E ratio?
Ligand Pharmaceuticals Incorporated trades at a price-to-earnings ratio of about 32.4 based on the latest data in our nightly-refreshed cache.
How fast is Ligand Pharmaceuticals Incorporated growing?
LGND's revenue grew at roughly 10.4% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Ligand Pharmaceuticals Incorporated's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.